Skip to main content
68th Annual Scientific Meeting Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Red Recording
Red Recording
Sig Meeting
Sig Meeting

Therapeutics (Industry)

(T 22) Rimegepant for the Preventive Treatment of Migraine: A Phase 3, Randomized, Double-blind, Placebo-controlled Study in Adults from China

    Presenting Author(s)

  • Jeremias Antinew, MD

    Clinical Development Medical Senior Director
    Pfizer Inc.
    Unionville, Connecticut, United States

    • Non-presenting author(s)

  • SY

    Shengyuan Yu, n/a

    Director
    Chinese PLA General Hospital, Beijing, China
    Beijing, Beijing, United States

    • Non-presenting Author(s)

  • Robert J. Fountaine, n/a

    Global Clinical Lead - CGRP Migraine Franchise
    Pfizer Inc., New York, NY, USA
    Groton, Connecticut, United States

  • LM

    Liheng Ma, n/a

    Pfizer (China) Research and Development Co Ltd, Shanghai, China, United States

  • XH

    Xiaoran Han, n/a

    Pfizer (China) Research and Development Co Ltd, Shanghai, China, United States

  • QZ

    Qi Zhong, n/a

    Pfizer (China) Research and Development Co Ltd, Shanghai, China, United States